Lantern Pharma (LTRN) Scheduled to Post Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Lantern Pharma (NASDAQ:LTRN) last posted its quarterly earnings results on Monday, March 18th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lantern Pharma Price Performance

LTRN stock opened at $6.42 on Wednesday. The business has a 50 day simple moving average of $6.96 and a 200-day simple moving average of $4.94. The firm has a market capitalization of $69.08 million, a PE ratio of -4.34 and a beta of 1.57. Lantern Pharma has a 1 year low of $2.38 and a 1 year high of $11.99.

Insider Buying and Selling at Lantern Pharma

In other Lantern Pharma news, major shareholder Aaron G.L. Fletcher sold 74,297 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $4.85, for a total value of $360,340.45. Following the sale, the insider now owns 62,088 shares of the company’s stock, valued at $301,126.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.92% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of Lantern Pharma in a report on Thursday, April 25th.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.